These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2715 related articles for article (PubMed ID: 31622696)

  • 21. Gut-liver axis: Pathophysiological concepts and clinical implications.
    Tilg H; Adolph TE; Trauner M
    Cell Metab; 2022 Nov; 34(11):1700-1718. PubMed ID: 36208625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease.
    Rochoń J; Kalinowski P; Szymanek-Majchrzak K; Grąt M
    World J Gastroenterol; 2024 Jun; 30(23):2964-2980. PubMed ID: 38946874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications.
    Chen J; Vitetta L
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32717871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Galangin Alleviates Alcohol-Provoked Liver Injury Associated with Gut Microbiota Disorder and Intestinal Barrier Dysfunction in Mice.
    Zhao Y; Li B; Deng H; Zhang C; Wang Y; Chen L; Teng H
    J Agric Food Chem; 2024 Oct; 72(40):22336-22348. PubMed ID: 39322623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alcoholic liver disease: the gut microbiome and liver cross talk.
    Hartmann P; Seebauer CT; Schnabl B
    Alcohol Clin Exp Res; 2015 May; 39(5):763-75. PubMed ID: 25872593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
    Hong M; Han DH; Hong J; Kim DJ; Suk KT
    Probiotics Antimicrob Proteins; 2019 Jun; 11(2):335-347. PubMed ID: 29687200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice.
    Chen P; Torralba M; Tan J; Embree M; Zengler K; Stärkel P; van Pijkeren JP; DePew J; Loomba R; Ho SB; Bajaj JS; Mutlu EA; Keshavarzian A; Tsukamoto H; Nelson KE; Fouts DE; Schnabl B
    Gastroenterology; 2015 Jan; 148(1):203-214.e16. PubMed ID: 25239591
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut microbiota and the liver.
    Federico A; Dallio M; Caprio GG; Ormando VM; Loguercio C
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):385-398. PubMed ID: 28927250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view.
    Chen HT; Huang HL; Li YQ; Xu HM; Zhou YJ
    World J Gastroenterol; 2020 Apr; 26(16):1901-1911. PubMed ID: 32390701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease.
    Dubinkina VB; Tyakht AV; Odintsova VY; Yarygin KS; Kovarsky BA; Pavlenko AV; Ischenko DS; Popenko AS; Alexeev DG; Taraskina AY; Nasyrova RF; Krupitsky EM; Shalikiani NV; Bakulin IG; Shcherbakov PL; Skorodumova LO; Larin AK; Kostryukova ES; Abdulkhakov RA; Abdulkhakov SR; Malanin SY; Ismagilova RK; Grigoryeva TV; Ilina EN; Govorun VM
    Microbiome; 2017 Oct; 5(1):141. PubMed ID: 29041989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases.
    Liu J; Yang D; Wang X; Asare PT; Zhang Q; Na L; Shao L
    Front Cell Infect Microbiol; 2022; 12():774335. PubMed ID: 35444959
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Li H; Shi J; Zhao L; Guan J; Liu F; Huo G; Li B
    J Agric Food Chem; 2021 Jan; 69(1):183-197. PubMed ID: 33353302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease.
    Maccioni L; Leclercq IA; Schnabl B; Stärkel P
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis.
    Nishikawa H; Enomoto H; Nishiguchi S; Iijima H
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32722100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
    Ji Y; Yin Y; Sun L; Zhang W
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbiota Dysbiosis and Gut Barrier Dysfunction Associated with Non-Alcoholic Fatty Liver Disease Are Modulated by a Specific Metabolic Cofactors' Combination.
    Quesada-Vázquez S; Bone C; Saha S; Triguero I; Colom-Pellicer M; Aragonès G; Hildebrand F; Del Bas JM; Caimari A; Beraza N; Escoté X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut microbiome in primary sclerosing cholangitis: A review.
    Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
    World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease.
    Chu H; Duan Y; Yang L; Schnabl B
    Gut; 2019 Feb; 68(2):359-370. PubMed ID: 30171065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 136.